Lexeo Therapeutics (LXEO) Competitors $6.15 +0.03 (+0.49%) (As of 09:25 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LXEO vs. RAPP, TYRA, EOLS, RLAY, PRTA, PLRX, CRON, REPL, AUTL, and ERASShould you be buying Lexeo Therapeutics stock or one of its competitors? The main competitors of Lexeo Therapeutics include Rapport Therapeutics (RAPP), Tyra Biosciences (TYRA), Evolus (EOLS), Relay Therapeutics (RLAY), Prothena (PRTA), Pliant Therapeutics (PLRX), Cronos Group (CRON), Replimune Group (REPL), Autolus Therapeutics (AUTL), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry. Lexeo Therapeutics vs. Rapport Therapeutics Tyra Biosciences Evolus Relay Therapeutics Prothena Pliant Therapeutics Cronos Group Replimune Group Autolus Therapeutics Erasca Rapport Therapeutics (NASDAQ:RAPP) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability. Is RAPP or LXEO more profitable? Rapport Therapeutics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A N/A N/A Lexeo Therapeutics N/A -57.66%-48.18% Does the MarketBeat Community believe in RAPP or LXEO? Lexeo Therapeutics received 17 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesLexeo TherapeuticsOutperform Votes19100.00% Underperform VotesNo Votes Which has higher earnings and valuation, RAPP or LXEO? Rapport Therapeutics has higher earnings, but lower revenue than Lexeo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$34.79MN/AN/ALexeo Therapeutics$650K312.89-$66.39M-$3.16-1.95 Does the media prefer RAPP or LXEO? In the previous week, Lexeo Therapeutics had 18 more articles in the media than Rapport Therapeutics. MarketBeat recorded 20 mentions for Lexeo Therapeutics and 2 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.77 beat Lexeo Therapeutics' score of -0.25 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rapport Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in RAPP or LXEO? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 4.5% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate RAPP or LXEO? Rapport Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 57.73%. Lexeo Therapeutics has a consensus target price of $22.71, indicating a potential upside of 269.34%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lexeo Therapeutics is more favorable than Rapport Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 SummaryLexeo Therapeutics beats Rapport Therapeutics on 9 of the 13 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXEO vs. The Competition Export to ExcelMetricLexeo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.38M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-1.9516.1687.8613.46Price / Sales312.89282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book1.464.436.946.30Net Income-$66.39M-$41.63M$119.12M$225.93M7 Day Performance-20.95%-4.73%-1.84%-1.32%1 Month Performance-41.54%-6.53%-3.65%0.60%1 Year Performance-44.14%25.63%31.64%26.23% Lexeo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXEOLexeo Therapeutics2.1432 of 5 stars$6.15+0.5%$22.71+269.3%-46.0%$203.38M$650,000.00-1.9558Analyst RevisionRAPPRapport Therapeutics1.8437 of 5 stars$22.19-0.4%$35.00+57.7%N/A$811.71MN/A0.00N/ANews CoverageTYRATyra Biosciences3.0757 of 5 stars$15.87-2.1%$31.00+95.3%+40.8%$803.02MN/A0.0020EOLSEvolus4.0221 of 5 stars$12.63+1.9%$23.00+82.1%+28.4%$799.73M$202.09M0.00170Positive NewsRLAYRelay Therapeutics3.2712 of 5 stars$4.66-2.9%$21.22+355.4%-44.5%$779.99M$25.55M0.00304Gap DownHigh Trading VolumePRTAProthena1.6436 of 5 stars$14.40+2.5%$61.86+329.6%-57.8%$774.86M$91.37M0.00173Analyst DowngradeAnalyst RevisionPLRXPliant Therapeutics3.4847 of 5 stars$12.73-0.5%$40.57+218.7%-11.4%$774.62M$1.58M0.0090CRONCronos Group1.7856 of 5 stars$2.01-1.0%$3.00+49.3%-3.8%$768.42M$87.24M-15.46356REPLReplimune Group4.2429 of 5 stars$11.23+2.6%$16.80+49.6%+10.3%$768.36MN/A-3.68210AUTLAutolus Therapeutics3.4682 of 5 stars$2.87+2.5%$10.15+253.7%-36.5%$763.68M$1.70M0.00330Analyst UpgradeERASErasca2.8027 of 5 stars$2.64-5.4%$6.08+130.4%+17.3%$746.41MN/A0.00126Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Rapport Therapeutics Competitors Tyra Biosciences Competitors Evolus Competitors Relay Therapeutics Competitors Prothena Competitors Pliant Therapeutics Competitors Cronos Group Competitors Replimune Group Competitors Autolus Therapeutics Competitors Erasca Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LXEO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
